Compounded Semaglutide: Where We Are in April 2026
The compounded-GLP-1 era is in fast retreat. The FDA declared the semaglutide shortage resolved in February 2025; the enforcement window then closed, the DOJ opened on Hims & Hers, and Novo Nordisk filed lawsuits. Here is exactly what is and is not legal in April 2026.
Got FDA Letters Mar 2026
Discretion End Date
Discretion End Date
How It Works
FDA declared the semaglutide injection shortage resolved on February 21, 2025. Once a drug is off the shortage list, the regulatory exception that allowed compounding "essentially a copy" of the commercial drug expires.
503A pharmacies (state-licensed): enforcement discretion ended April 22, 2025. 503B facilities (outsourcing): May 22, 2025. Both windows have closed; production after these dates draws active FDA enforcement.
March 3, 2026: FDA issued 30 warning letters to telehealth companies. Targets included false equivalence claims, private-label obscuration, and Ozempic/Wegovy-mimicking branding. Future actions threatened: seizure and injunction.
Compounding remains legal only when a prescriber documents a "significant difference" for an individual patient (e.g., dye allergy in commercial product, inability to swallow pills). Adding B12 to mimic a "different" formulation is explicitly NOT a significant difference if strengths are within 10% of the commercial drug.
What the Data Shows
Key Takeaways
- FDA declared the semaglutide shortage resolved February 21, 2025
- 503A pharmacy enforcement discretion ended April 22, 2025; 503B ended May 22, 2025
- March 3, 2026: FDA issued 30 warning letters to telehealth companies marketing compounded GLP-1s
- February 2026: DOJ opened investigation into Hims & Hers; company pulled compounded semaglutide pill
- Novo Nordisk filed patent and safety/efficacy lawsuits against Hims & Hers
- April 1, 2026 FDA clarification: adding B12 or trivial modifications does not make a compounded version legal
- Compounded semaglutide is still legal only with documented patient-specific significant difference
- How aggressively FDA will pursue seizures and injunctions
- Whether other "personalized" providers (beyond Hims & Hers) face DOJ action
- When FDA will return to discretion if a future shortage occurs
- How patients on compounded protocols transition cleanly to brand-name supply
- Whether state-level pharmacy board actions amplify federal enforcement
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Only narrowly. Since the FDA declared the semaglutide shortage resolved on February 21, 2025, the regulatory exception that enabled mass compounding of "essentially a copy" of the commercial drug has expired. Compounding remains legal only when a licensed prescriber documents a clinically significant difference for an individual patient — for example, an allergy to a dye in the commercial product, or an inability to swallow pills requiring a liquid formulation. Adding B12 or making a trivial modification does NOT create a legal compound.
What happened to Hims & Hers compounded semaglutide?
In February 2026, the Department of Justice opened an investigation into Hims & Hers for potential violations of the Food, Drug & Cosmetics Act related to semaglutide compounding. Hims & Hers stopped selling its compounded semaglutide pill. Separately, Novo Nordisk filed a lawsuit alleging patent infringement and deceptive safety/efficacy claims about the compounded product.
I'm currently on compounded semaglutide — what should I do?
First: ensure you have a verified prescription from a licensed prescriber. Second: discuss transition options. Manufacturer cash-pay programs are now substantially cheaper than they were in 2024: NovoCare offers Wegovy injections for $199–$349/mo and a Wegovy pill for $149–$299/mo. LillyDirect offers Zepbound vials for $299–$499/mo. Most compounded users can transition to brand-name supply at comparable cost without insurance coverage.
Are research peptides ("for laboratory use") a way around this?
No. Research peptides are sold under "for laboratory use only" labeling and are not legal for human consumption. They are not subject to the same quality controls as compounded or commercial drugs, and many vendors do not provide third-party COAs. Using research peptides for personal weight loss carries unverified content, contamination risk, and unknown stability — and is regulatory gray-to-black depending on jurisdiction.
Will the FDA bring back compounding if there's another shortage?
In principle yes — the discretion windows are tied to shortage status. If semaglutide returns to the FDA shortage list, the 503A and 503B compounding allowances would re-open. As of April 2026, supply has stabilized and there is no indication this will reverse near-term.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
Educational purposes only. Not medical advice.
Regulatory and legal status of compounded medications evolves rapidly. Verify current FDA guidance and applicable state pharmacy law before relying on this page for legal interpretation.